DK3097926T3 - Sammensætninger og fremgangsmåder til forstærkning af immunreaktioner på Eimeria - Google Patents

Sammensætninger og fremgangsmåder til forstærkning af immunreaktioner på Eimeria Download PDF

Info

Publication number
DK3097926T3
DK3097926T3 DK16175274.6T DK16175274T DK3097926T3 DK 3097926 T3 DK3097926 T3 DK 3097926T3 DK 16175274 T DK16175274 T DK 16175274T DK 3097926 T3 DK3097926 T3 DK 3097926T3
Authority
DK
Denmark
Prior art keywords
eimeria
compositions
methods
immune reactions
boosting immune
Prior art date
Application number
DK16175274.6T
Other languages
English (en)
Inventor
Walter Bottje
Billy Hargis
Luc Berghman
Young Min Kwon
Kimberly Cole
Sherryll Layton
Saeed El-Ashram
John Barta
Guillermo Tellez
Mandy Cox
Original Assignee
Univ Arkansas
Univ Guelph
Texas A & M Univ Sys
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arkansas, Univ Guelph, Texas A & M Univ Sys filed Critical Univ Arkansas
Application granted granted Critical
Publication of DK3097926T3 publication Critical patent/DK3097926T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/455—Eimeria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DK16175274.6T 2007-11-01 2008-11-03 Sammensætninger og fremgangsmåder til forstærkning af immunreaktioner på Eimeria DK3097926T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98461207P 2007-11-01 2007-11-01
EP08843740.5A EP2214701B1 (en) 2007-11-01 2008-11-03 Compositions and methods of enhancing immune responses to eimeria

Publications (1)

Publication Number Publication Date
DK3097926T3 true DK3097926T3 (da) 2019-12-16

Family

ID=40591796

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08843740.5T DK2214701T3 (da) 2007-11-01 2008-11-03 Sammensætninger og fremgangsmåder til forbedring af immunreaktioner på eimeria
DK16175274.6T DK3097926T3 (da) 2007-11-01 2008-11-03 Sammensætninger og fremgangsmåder til forstærkning af immunreaktioner på Eimeria

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK08843740.5T DK2214701T3 (da) 2007-11-01 2008-11-03 Sammensætninger og fremgangsmåder til forbedring af immunreaktioner på eimeria

Country Status (15)

Country Link
US (3) US8956849B2 (da)
EP (2) EP3097926B1 (da)
JP (1) JP5480812B2 (da)
CN (2) CN101969990B (da)
AU (1) AU2008318357B2 (da)
BR (1) BRPI0819229B1 (da)
CA (3) CA3051748C (da)
DK (2) DK2214701T3 (da)
ES (2) ES2761693T3 (da)
HK (1) HK1146575A1 (da)
HU (2) HUE047164T2 (da)
NZ (2) NZ585777A (da)
PL (2) PL3097926T3 (da)
PT (2) PT3097926T (da)
WO (1) WO2009059298A2 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2517723B1 (en) * 2006-09-18 2019-11-06 The Board of Trustees of The University of Arkansas Compositions and methods of enhancing immune responses
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
BRPI0818736A2 (pt) 2007-10-30 2017-06-13 Univ Arkansas composições e métodos para intensificar imunorrepostas à bactéria flagelada
HUE047164T2 (hu) * 2007-11-01 2020-04-28 Univ Arkansas Kompozíciók és eljárások eimeria elleni immunválasz fokozására
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
EP2525817B8 (en) 2010-01-21 2017-09-20 The Board of Trustees of The University of Arkansas Vaccine vectors and methods of enhancing immune responses
HUE046858T2 (hu) * 2010-06-09 2020-03-30 Univ Arkansas Vakcina és eljárások campylobacter fertõzés csökkentésére
AU2013203641B2 (en) * 2011-04-13 2014-08-21 Epizyme, Inc. Aryl-or heteroaryl-substituted benzene compounds
US9580482B2 (en) 2012-02-17 2017-02-28 Children's Medical Center Corporation Conformation-stabilized TRAP antigens
MY173328A (en) * 2013-02-14 2020-01-16 Texas A & M Univ Sys Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
EA033538B1 (ru) 2013-03-15 2019-10-31 Univ Arkansas Композиции и способы усиления иммунного ответа на кишечные патогены
US10647946B2 (en) 2015-05-08 2020-05-12 Novozymes A/S Alpha-amylase variants and polynucleotides encoding same
TWI758288B (zh) 2016-05-03 2022-03-21 阿肯色州大學董事會 包含免疫刺激性及抗原性多肽的酵母菌疫苗載體以及其使用方法
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN110468069B (zh) * 2019-08-19 2020-11-06 中国水产科学研究院长江水产研究所 一种干酪乳杆菌yfi-5及其在抗鲤疱疹病毒ii型中的应用
CN113304254A (zh) * 2021-06-07 2021-08-27 吉林大学 一种微小隐孢子虫Cp15重组侵入型乳酸菌活载体疫苗

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015689A1 (en) 1991-03-05 1992-09-17 The Wellcome Foundation Limited Expression of recombinant proteins in attenuated bacteria
US5961974A (en) * 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
JP3308534B2 (ja) 1991-10-25 2002-07-29 イミュネックス・コーポレーション 新規なサイトカイン
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5981724A (en) 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
ATE173166T1 (de) 1992-09-04 1998-11-15 Univ Saskatchewan Neue bakterielle impfstoffe unter verwendung von impfstämmen von pathogenen bakterien
JP4242447B2 (ja) * 1993-01-22 2009-03-25 イミュネックス・コーポレーション Ｃｄ４０リガンド遺伝子の突然変異の検出および治療
WO1995014487A1 (en) 1993-11-24 1995-06-01 The Australian National University Treatment of viral disease with cd40l peptide
CA2188165C (en) * 1994-04-28 2007-08-28 Marilyn Kehry Methods for proliferating and differentiating b cells, and uses thereof
PT812206E (pt) 1995-03-01 2002-11-29 Immunex Corp Proteina de ligacao a cd40 para estimulacao de uma resposta imunitaria
DE69631331T2 (de) 1995-06-07 2004-11-18 Immunex Corp., Seattle Cd40l mutein
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US6306387B1 (en) 1997-05-29 2001-10-23 The Research Foundation Of State University Of New York Antigen delivery system
US20030045492A1 (en) 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
US6969609B1 (en) 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
CA2223225A1 (en) 1997-11-28 1999-05-28 Canadian Red Cross Society Method for inhibiting in vivo immune response
EP1059932A1 (en) 1997-12-19 2000-12-20 Immunex Corporation Method for reducing susceptibility to hiv infection
GB9806449D0 (en) 1998-03-25 1998-05-27 Peptide Therapeutics Ltd Attenuated bacteria useful in vaccines
US6190669B1 (en) 1998-05-13 2001-02-20 University Of Maryland, Baltimore Attenuated mutants of salmonella which constitutively express the Vi antigen
WO2000014240A2 (en) 1998-09-04 2000-03-16 Creatogen Aktiengesellschaft Attenuated salmonella sp12 mutants as antigen carriers
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
EP1067194A1 (en) 1999-04-16 2001-01-10 F. Hoffmann-La Roche Ag Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
EP1173589A1 (en) 1999-04-16 2002-01-23 F. Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
US7803765B2 (en) * 1999-05-05 2010-09-28 Phylogica Limited Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom
AU1084901A (en) * 1999-10-14 2001-04-23 Martha S. Hayden-Ledbetter Dna vaccines encoding antigen linked to a domain that binds cd40
DE60011560T2 (de) 1999-12-28 2005-08-18 Akzo Nobel N.V. Salmonella Impfstoff, der keinen Antikörper gegen Flagellin oder gegen Flagella induziert
CA2399790C (en) 2000-02-02 2012-10-30 Ralph A. Tripp Cd40 ligand adjuvant for respiratory syncytial virus
AU5695701A (en) 2000-03-17 2001-10-03 Upjohn Co Salmonella vaccine materials and methods
GB0015426D0 (en) 2000-06-24 2000-08-16 Univ Southampton Method for generating soluble highly multimeric proteins
WO2002000232A2 (en) 2000-06-26 2002-01-03 Maxygen, Inc. Methods and compositions for developing spore display systems for medicinal and industrial applications
WO2002036769A2 (en) 2000-10-31 2002-05-10 F. Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
US6855493B2 (en) * 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
MXPA03010507A (es) 2001-05-15 2005-07-25 Johnson & Johnson Activacion ex vivo para generar linfocitos c citotoxicos espedificos para antigenos no tumorales para tratar enfermedades autoinmunes y alergicas.
CN100348608C (zh) * 2001-07-06 2007-11-14 Abic特瓦生物实验室有限公司 编码重组的来源于巨型艾美球虫子孢子/裂殖子的250kDa抗原的核酸,和它们的应用
ZA200400479B (en) * 2001-07-06 2006-05-31 Abic Biolog Lab Teva Nucleic acids encoding recombinant 56 a 82 KDA antigens from gametocytes of Eimeria maxima and their use
ITMI20011986A1 (it) 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
US7378089B2 (en) 2001-10-02 2008-05-27 The Board Of Trustees Of The Leland Stanford Junior University Gene therapy for the prevention of autoimmune disease
MXPA04005909A (es) * 2001-12-21 2005-05-17 Immunex Corp Polipeptidos recombinantes.
US6929798B2 (en) * 2002-02-13 2005-08-16 Immunology Laboratories, Inc. Compositions and methods for treatment of microbial infections
US6923958B2 (en) 2002-03-02 2005-08-02 The Scripps Research Institute DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
US8133493B2 (en) 2002-04-15 2012-03-13 Washington University Regulated attenuation of live vaccines to enhance cross-protective immunogenicity
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
US20060014248A1 (en) 2003-01-06 2006-01-19 Xencor, Inc. TNF super family members with altered immunogenicity
US20050181994A1 (en) 2003-01-06 2005-08-18 Xencor, Inc. Novel variants of CD40L protein
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
EP1673389A2 (en) 2003-10-10 2006-06-28 Xencor Inc. Novel variants of cd40l protein
US8828957B2 (en) 2003-12-11 2014-09-09 Microvax, Llc Methods for generating immunity to antigen
WO2005058950A2 (en) 2003-12-11 2005-06-30 Sidney Kimmel Cancer Center Methods for generating immunity to antigen
WO2005113598A2 (en) 2004-05-21 2005-12-01 Xencor, Inc. Tnf super family members with altered immunogenicity
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
KR101243577B1 (ko) 2004-10-07 2013-03-20 아고스 쎄라퓨틱스, 인코포레이티드 성숙 수지상 세포 조성물 및 그의 배양 방법
WO2006105972A1 (en) 2005-04-07 2006-10-12 Universite Libre De Bruxelles Transgenic organism expressing cd40l and uses thereof
WO2006130525A2 (en) 2005-05-31 2006-12-07 Sidney Kimmel Cancer Center Methods for immunotherapy of cancer
JP2009511452A (ja) 2005-10-07 2009-03-19 プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダ Ｃ型肝炎の予防および治療のための免疫刺激物質の組合せ
JP2009514536A (ja) 2005-11-07 2009-04-09 シドニー キンメル キャンサー センター Ｃｄ４０リガンド融合蛋白質ワクチン
DE102005054643B3 (de) 2005-11-10 2007-02-15 Assa Abloy Sicherheitstechnik Gmbh Schließzylinder
WO2007054658A1 (en) 2005-11-14 2007-05-18 King's College London Control of immune responses
CU23576A1 (es) * 2006-02-28 2010-09-30 Ct Ingenieria Genetica Biotech Antígenos vacunales quiméricos contra el virus de la influenza aviar
WO2007103048A2 (en) 2006-03-01 2007-09-13 Regents Of The University Of Colorado Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
WO2007106073A2 (en) 2006-03-02 2007-09-20 University Of Massachusetts Modified pathogens for use as vaccines
FR2898905B1 (fr) * 2006-03-24 2008-05-09 Rhodia Recherches & Tech Composition polyisocyanate a proprietes anti-chocs ameliorees
WO2008027394A2 (en) * 2006-08-28 2008-03-06 The Wistar Institute Of Anatomy And Biology Constructs for enhancing immune responses
EP2517723B1 (en) * 2006-09-18 2019-11-06 The Board of Trustees of The University of Arkansas Compositions and methods of enhancing immune responses
WO2008109825A2 (en) 2007-03-08 2008-09-12 Mayo Foundation For Medical Education And Research Inducing immune-mediated tumor cell death
CN101024076B (zh) * 2007-03-29 2010-08-18 中国农业大学 球虫的新用途
CA2860950C (en) * 2007-07-10 2017-08-01 Apogenix Gmbh Tnf superfamily collectin fusion proteins
BRPI0818736A2 (pt) * 2007-10-30 2017-06-13 Univ Arkansas composições e métodos para intensificar imunorrepostas à bactéria flagelada
HUE047164T2 (hu) 2007-11-01 2020-04-28 Univ Arkansas Kompozíciók és eljárások eimeria elleni immunválasz fokozására
SI2310509T1 (sl) * 2008-07-21 2015-07-31 Apogenix Gmbh TNFSF enoverižne molekule
US8316310B2 (en) 2008-08-05 2012-11-20 International Business Machines Corporation System and method for human identification proof for use in virtual environments
PL2184229T3 (pl) * 2008-11-11 2013-04-30 Agustawestland Spa Wirnik śmigłowca
US20100150958A1 (en) * 2008-12-15 2010-06-17 Vectogen Pty Ltd. Methods and Compositions for Use of a Coccidiosis Vaccine
EP2525817B8 (en) * 2010-01-21 2017-09-20 The Board of Trustees of The University of Arkansas Vaccine vectors and methods of enhancing immune responses
HUE051439T2 (hu) * 2011-10-11 2021-03-01 Viela Bio Inc CD40L-re specifikus, TN3-eredetû állványok és alkalmazásuk
US20140079704A1 (en) * 2012-09-11 2014-03-20 The Texas A&M University System BI-Specific Diabodies For Masking And Targeting Vaccines
AU2013338153B2 (en) * 2012-10-29 2018-06-21 The Board Of Trustees Of The University Of Arkansas Novel mucosal adjuvants and delivery systems
MY173328A (en) * 2013-02-14 2020-01-16 Texas A & M Univ Sys Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
EA033538B1 (ru) * 2013-03-15 2019-10-31 Univ Arkansas Композиции и способы усиления иммунного ответа на кишечные патогены
AU2015269415A1 (en) * 2014-06-05 2017-01-05 The Board Of Trustees Of The University Of Arkansas Antibody guided vaccines and methods of use for generation of rapid mature immune responses
US20160090603A1 (en) * 2014-09-30 2016-03-31 Sandia Corporation Delivery platforms for the domestication of algae and plants
KR20230148844A (ko) * 2016-03-29 2023-10-25 유니버시티 오브 써던 캘리포니아 암을 표적하는 키메라 항원 수용체
MX2018014630A (es) * 2016-05-27 2019-06-10 Abbvie Biotherapeutics Inc Anticuerpos anti-cd40 y sus usos.
CA3033788A1 (en) * 2016-08-17 2018-02-22 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof

Also Published As

Publication number Publication date
WO2009059298A2 (en) 2009-05-07
BRPI0819229A2 (pt) 2015-05-05
WO2009059298A8 (en) 2010-08-05
DK2214701T3 (da) 2016-12-12
EP2214701A2 (en) 2010-08-11
ES2761693T3 (es) 2020-05-20
CA3051748A1 (en) 2009-05-07
WO2009059298A3 (en) 2009-09-24
PL3097926T3 (pl) 2020-04-30
CN103893747A (zh) 2014-07-02
HK1146575A1 (zh) 2011-06-24
HUE047164T2 (hu) 2020-04-28
EP3097926A1 (en) 2016-11-30
CA2704422C (en) 2019-09-24
EP2214701B1 (en) 2016-08-03
US10016493B2 (en) 2018-07-10
CN101969990A (zh) 2011-02-09
US10842858B2 (en) 2020-11-24
PT3097926T (pt) 2020-01-08
ES2599905T3 (es) 2017-02-06
AU2008318357B2 (en) 2015-01-22
CA3051748C (en) 2022-07-12
NZ601880A (en) 2013-12-20
US8956849B2 (en) 2015-02-17
PL2214701T3 (pl) 2017-01-31
CN103893747B (zh) 2016-01-06
CA3156538A1 (en) 2009-05-07
AU2008318357A2 (en) 2010-06-24
CN101969990B (zh) 2014-07-09
BRPI0819229B1 (pt) 2019-01-22
CA3156538C (en) 2023-12-12
JP5480812B2 (ja) 2014-04-23
HUE030655T2 (en) 2017-05-29
EP3097926B1 (en) 2019-10-02
US20180333474A1 (en) 2018-11-22
JP2011503003A (ja) 2011-01-27
AU2008318357A1 (en) 2009-05-07
EP2214701A4 (en) 2011-06-01
PT2214701T (pt) 2016-11-02
CA2704422A1 (en) 2009-05-07
NZ585777A (en) 2012-09-28
US20150216954A1 (en) 2015-08-06
US20110111015A1 (en) 2011-05-12

Similar Documents

Publication Publication Date Title
DK3097926T3 (da) Sammensætninger og fremgangsmåder til forstærkning af immunreaktioner på Eimeria
DK2066339T3 (da) Sammensætninger og fremgangsmåder til forstærkning af immunreaktioner
DK2203478T3 (da) Sammensætninger og fremgangsmåder til anvendelse af antistoffer mod sclerostin
DK3156069T3 (da) Sammensætninger, fremgangsmåder, og kits til fremkaldelse af et immunrespons
DK2470656T3 (da) Sammensætning til hæmning af genekspression og anvendelser heraf
DK2653873T3 (da) Sammensætninger og anvendelser til behandling af multipel sklerose
DK3178490T3 (da) RSV F-proteinsammensætninger og fremgangsmåder til fremstilling af disse
DK2155188T3 (da) Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft
DK2427166T3 (da) Tabletfremstillingsmodul og fremgangsmåde til kontinuerlig fremstilling af tabletter
DK2087002T3 (da) Sammensætninger og fremgangsmåder til binding af sphingosin-1-phosphat
DK3081315T3 (da) Fremgangsmåde og system til sortering af fødevarer
DK2245064T3 (da) BINDINGSELEMENTER TIL INTERLEUKIN-4-RECEPTOR-ALFA (IL-4Ralfa)
DK2081669T3 (da) Fremgangsmåde og anordning til fremstilling af granulater
DK2894165T3 (da) Fremgangsmåder og sammensætninger til behandling af komplementforbundne forstyrrelser
DK2518655T3 (da) Anordning og fremgangsmåde til forebyggelse af hypoglykæmi
DK2188336T3 (da) Sammensætning omfattende et eller flere hydrofobt modificerede polyacrylamider og fremgangsmåde til anvendelse af sammensætningen
DK2323638T3 (da) Sammensætninger og fremgangsmåder til behandling af osteoartritis
DK2346552T4 (da) Lægemiddelafgivelsesanordning og fremgangsmåde til fremstilling af en lægemiddelafgivelsesanordning
DK2061561T3 (da) Sammensætninger til behandling af cancer
DK2270818T3 (da) Polyelektrolyt og fremgangsmåde til fremstilling af polyelektrolytten
DK2215031T3 (da) Fremgangsmåde til bearbejdning af pozzolaner
DK2068930T3 (da) Sammensætninger og fremgangsmåder under anvendelse af anti-CS1-antistoffer til at behandle multiple myelomer
DK2126801T3 (da) Fremgangsmåde til udvælgelse af information
DK3106875T3 (da) Fremgangsmåde til detektering af cancer
DK2598500T3 (da) Sammensætninger og fremgangsmåder til hæmning af jak-reaktionsvejen